��������

Ms. Segal brings more than 20 years of experience leading the development and execution of global regulatory strategies across all phases of drug development for a range of therapeutic areas including oncology, hematology, inflammatory diseases, and neurology. She most recently served as Senior Vice President, Regulatory Affairs and Quality at Scholar Rock where she directed all global regulatory efforts, oversaw quality and compliance, and contributed to overall R&D pipeline strategy. Prior to that, Ms. Segal held positions of increasing responsibility at biopharmaceutical companies including Q32 Bio, Solid Biosciences. In addition, while at Biogen, she was responsible for leading the global regulatory team where they attained marketing approvals of ELOCTATE®️ and ALPROLIX®️, treatments for Hemophilia A and Hemophilia B respectively, including approvals in the US, EU, Japan, Australia, and Canada.